TRANSGENE news, videos and press releases - Page 3
For more news please use our advanced search feature.
TRANSGENE - More news...
TRANSGENE - More news...
- Transgene Announces Upcoming Investor Meetings
- Transgene: Q1 2022 Financial Position and Business Update
- Transgene to Present New Positive Preliminary Phase I Clinical Data at AACR 2022, Reinforcing the Potential of TG4050
- Availability of Transgene’s 2021 Universal Registration Document
- Transgene: Availability of Preparatory Documents for the Combined General Meeting of May 25, 2022
- Transgene’s Board of Directors Strengthens Its Governance and Proposes the Appointment of Dr. Alessandro Riva as Independent Chairman
- Transgene Confirms the Potential of Its Two Innovative Platforms and Expects Significant Clinical Results in 2022
- Transgene to Present New Positive Preliminary Phase I Data on TG4050 (myvac® platform), its Individualized Therapeutic Cancer Vaccine, at AACR 2022
- Transgene and BioInvent Announce Poster Presentation on BT-001, a Novel Antibody-encoding Oncolytic Virus, at AACR 2022
- Transgene Appoints Steven Bloom as Chief Business Officer
- Transgene and BioInvent Joint JITC Publication Demonstrates the Potential of BT-001 Oncolytic Virus to Provide Therapeutic Benefit Beyond Current Anti-PD1/ Anti-CTLA-4 Immune Checkpoint Blockade
- Transgene and PersonGen Announce Collaboration to Evaluate a New Combination Therapy Against Solid Tumors
- Transgene Announces Financial Calendar for 2022
- Transgene: Balance Sheet of the Liquidity Contract with Natixis Oddo BHF SCA as of December 31, 2021
- Transgene Announces Investor Meetings for January 2022
- Transgene announces License Option Exercise by AstraZeneca for an Oncolytic Virus Generated by Transgene’s Invir.IO™ Platform
- Transgene and NEC Announce Positive Preliminary Data From Phase I Studies of TG4050, a Novel Individualized Neoantigen Cancer Vaccine
- Transgene and BioInvent Present Preclinical Data Highlighting the Robust Anti-Tumoral Activity of BT-001 Oncolytic Virus at SITC 2021
- Transgene Reports Business Update and Q3 2021 Financial Position
- Transgene and BioInvent to Present Preclinical Data on BT-001 Oncolytic Virus at SITC 2021
- Availability of Transgene’s Half-Year Financial Report as of June 30, 2021
- Transgene’s Two Innovative Platforms Progressing Well - Financial Visibility Extended Until End 2023
- Transgene Presents Data From Phase I Clinical Trial Confirming the Potential of the Oncolytic Virus TG6002
- Transgene Announces Upcoming Investor Meetings
- Transgene Participates in New Cancer Research Consortium
- Transgene: Balance Sheet of the Liquidity Contract With Natixis Oddo BHF SCA as of June 30, 2021
- First Head & Neck Cancer Patient Enrolled in the UK in a Phase I Trial with TG4050 (myvac® Platform), Transgene’s Innovative Individualized Immunotherapy
- Transgene: First Patient Enrolled in Expanded Phase II Clinical Trial of TG4001 + Avelumab Vs Avelumab Alone in Patients With HPV16-positive Anogenital Cancers
- Transgene Announces the Success of Its Capital Increase via a Private Placement
- Transgene Launches a Capital Increase via a Private Placement
